Latest Mental Health News

Doctor Care Anywhere has reported a profitable first half of 2025, driven by strong margin improvements and operational efficiencies. The telehealth provider’s strategic expansion and app enhancements signal promising growth ahead.

Doctor Care Anywhere Group PLC has reported its first-ever profit for the six months ended June 2025, marking a pivotal turnaround driven by operational efficiencies and pricing strategies despite a revenue dip.

Medibank has reported strong full-year results for 2025, with underlying net profit rising 8.5% and record policyholder growth, underpinned by disciplined cost management and strategic health investments.

Medibank Private Limited reported steady revenue growth and stable profit for FY25, while navigating ongoing cybercrime-related expenses and regulatory scrutiny. The insurer also announced increased dividends and outlined strategic investments in health services and digital transformation.

Qoria Limited reported a robust FY2025 with 25% growth in annual recurring revenue and a 684% jump in EBITDA, underscoring its expanding leadership in global K12 safety and wellbeing platforms.

RAM Essential Services Property Fund reported solid FY25 results, highlighting portfolio growth, strategic capital recycling, and a clear transition towards a pure healthcare real estate focus.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Peet Limited delivered a robust FY25 performance with a 60% jump in net operating profit and a strong sales pipeline, while initiating a strategic review to capitalize on favorable market conditions.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

IPH Limited reported a solid 16.5% revenue increase to $710.3 million for FY25, driven by strategic acquisitions in Canada and strong organic growth in Asia and ANZ. Despite ongoing delays at the Canadian Intellectual Property Office, the company achieved higher earnings and dividends, setting the stage for further operational efficiencies and technology investments.

Dexus’s 2025 annual results reveal stable cash flows, robust occupancy rates, and a positive shift in property valuations, underscoring its resilience amid evolving market conditions. The company’s sustainability leadership and strategic divestments position it well for the next growth phase.

Dexus has reported FY25 results that meet guidance, showcasing resilience in its office and industrial portfolios alongside strong funds management performance. The company signals optimism for the next phase of the real estate cycle despite ongoing market uncertainties.